Belluscura Signs Distribution Agreement

Belluscura PLC
01 August 2023
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Belluscura plc

("Belluscura" or the "Company" or "Group")

 

 Belluscura Signs Distribution Agreement with Subsidiary of World's Largest Drug Distributor

 

McKesson Medical-Surgical Corporation expands its respiratory offerings by entering into a distribution agreement with Belluscura

 

LONDON, U.K. AND PLANO, TX, U.S. (01 August 2023). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has signed a distribution agreement with McKesson Medical-Surgical, a division of McKesson, the 9th largest company by revenue in the US. McKesson delivers a third of all pharmaceuticals used in North America and operates the fourth-largest pharmacy chain in North America.

 

The X-PLOR® portable oxygen concentrator will now be available to McKesson's customers through their online catalogue.

 

Robert Fary. Sr Vice President of Global Sales, Belluscura plc, commented:

"We continue to expand the distribution of the X-PLOR throughout the US and this exciting agreement will extend our reach to patients seeking access to best-in-class devices." 

 

Robert Rauker, Chief Executive Officer, Belluscura plc, commented:

"We are very pleased that McKesson, one of the largest distributors of pharmaceuticals and medical devices in North America, has chosen the X-PLOR to be offered through their catalogue. This significant distribution agreement will mean that more Americans can purchase our devices throughout the country, broadening our product distribution and making supplemental oxygen more easily accessible."

 

 

For further information please contact:

 Belluscura plc

Tel: +44 (0)20 3128 8100

Adam Reynolds, Chairman
Robert Rauker, Chief Executive Officer
Anthony Dyer, Chief Financial Officer




SPARK Advisory Partners Limited

Nominated Adviser

Tel: +44 (0)20 3368 3550

Neil Baldwin / Jade Bayat




Dowgate Capital Limited

Broker

Tel: +44 (0)20 3903 7715

James Serjeant / Russell Cook




MHP

Financial PR & Investor Relations

Tel: +44 (0)20 3128 8100

email: Belluscura@mhpgroup.com

Katie Hunt/Matthew Taylor


 

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Belluscura (BELL)
UK 100

Latest directors dealings